Hepatitis B Topics HBV Treatment
Coverage of the 2014 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Tuesday, 02 December 2014 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.
Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.
12/2/14
AASLD 2014: Tenofovir Continues to Work Well Against Hepatitis B Virus for 8 Years
- Details
- Category: HBV Treatment
- Published on Wednesday, 19 November 2014 00:00
- Written by Liz Highleyman
Most chronic hepatitis B patients treated with tenofovir (Viread) for 8 years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston.Serological response rates continued to increase over time and kidney and bone-related side effects remained uncommon.
AASLD Liver Meeting Starts this Weekend in Boston
- Details
- Category: Hepatitis B
- Published on Thursday, 06 November 2014 00:00
- Written by HIVandHepatitis.com
The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this weekend, running through November 11 at the Hynes Convention Center in Boston. Once again, this year's meeting will highlight interferon-free direct-acting antiviral regimens for hepatitis C.
AASLD 2014: Pegylated Interferon + Tenofovir Improves Odds of HBsAg Loss in Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Friday, 14 November 2014 00:00
- Written by Liz Highleyman
People with chronic hepatitis B virus (HBV) infection are more likely to experience favorable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir -- although even then the cure rate falls short of 10%, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.
IDWeek 2014: Hepatitis B Relapse Is Common After Stopping Antiviral Therapy
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 04 November 2014 00:00
- Written by Liz Highleyman
Hepatitis B virus (HBV) rebounded in nearly 80% of people treated with fully or partially suppressive antiviral therapy using adefovir (Hepsera), entecavir (Baraclude), lamivudine (Epivir), or tenofovir (Viread), indicating that long-term therapy is usually needed to control the virus, researchers reported at IDWeek 2014 last month in Philadelphia.
Web Design and Development by